Catalyst

Slingshot members are tracking this event:

FDA Approves Janssen's (JNJ) INVOKAMET XR in Treatment of Adults with Type 2 Diabetes

Source Link:
http://www.prnewswire.com/news-releases/us-fda-approves-invokamet-xr-canagliflozin--metformin-hydrochloride-extended-release-for-the-treatment-of-adults-with-type-2-diabetes-300331687.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 21, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Invokamet Xr, Adults With Type 2 Diabetes, Fda Approval
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.